Results 131 to 140 of about 485 (159)

Do Ditans and Gepants Have a Place in Acute Migraine Treatment?

Pharmacy Today, 2022
Clarissa Chan
exaly   +2 more sources

Lasmiditan, a Novel Abortive Agent for Migraine Therapy – From Triptans to Ditans

International Journal of Pharmaceutical Sciences Review and Research, 2023
Rishika Addla, Soni Gaddam, Satyanarayana SV Padi   +2 more
exaly   +2 more sources

The Journey of the Non-Vascular Relief for Migraine: From ‘Triptans’ to ‘Ditans’

Current Clinical Pharmacology, 2017
Migraine is a recurrent, disabling, complex and highly prevalent neurological disorder. The mystery behind the cause of migraine is continuously evolving, according to the scientific understanding of the disease. This growing understanding helps to identify novel therapeutic targets for the management of migraine to treat the ailing migraineurs.
Mageshwaran Lakshmanan, Vikneswaran Gunaseelan   +1 more
exaly   +3 more sources

Ditans vs Gepants

Neurology India, 2021
Background: An acute attack of migraine, incapacitates the migraineurs, and is widely prevalent. And to warden off its symptoms, recently two groups of drugs have been approved and launched. Objective: The aim of this systematic review
Alok, Singh, Dhyuti, Gupta, Abhishek, Singh   +2 more
openaire   +2 more sources

New Treatments for Migraine: CGRP Monoclonal Antibodies, Gepants, and Ditans

BMJ, The
Rebecca Burch
exaly   +5 more sources

Une nouvelle génération de traitements spécifiques de la crise migraineuse : ditans et gépants

Douleur Et Analgesie, 2020
Les traitements de référence de la crise migraineuse sont actuellement les triptans, dont la limite d’usage concerne les patients avec antécédents cardiovasculaires, méconnus chez certains patients, et la tolérabilité, les effets latéraux affectant près d’un tiers des patients.
G Mick
exaly   +2 more sources

Ditans and Gepants: Hope or False Promise for Menstrual Migraine?

Neurological Sciences
Menstrual migraine (MM) is a debilitating migraine subtype associated with hormonal fluctuations, often resistant to conventional treatments. Gepants, novel calcitonin generelated peptide (CGRP) receptor antagonists, and ditans, serotonin 5-HT1F receptor agonists, offer potential alternatives to triptans due to their non-vasoconstrictive properties ...
Gonçalo Cabral
exaly   +3 more sources

Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk

Headache, 2019
Abstract Premise The science of migraine pathophysiology has advanced significantly since the 1930’s. Imaging techniques, neurochemical analysis, clinical trials, and the clinical experience of providers treating migraine patients have not only sharpened our understanding of the disease, but ...
Brad C Klein, Paul Mathew
exaly   +3 more sources

[New Therapeutic Era for Migraine Attacks With Recently Approved Monoclonal Antibodies, Ditans and Gepants].

Revista De Neurologia
Treatment of migraine attacks is advised in all patients, using non-steroidal anti-inflammatory drugs when the pain is mild and triptans when the pain intensity is moderate-severe. However, the effectiveness of these drugs is moderate, a high percentage of patients have side effects, and triptans are contraindicated in people with a history of stroke ...
Pablo Irimia, Sonia Quintas
exaly   +2 more sources

[Gepants and Ditans].

Brain and nerve = Shinkei kenkyu no shinpo, 2021
The calcitonin gene-related peptide (CGRP) has been shown to play a major role in the pathophysiology of migraine in recent years. Studies have suggested that blocking CGRP signaling is an effective preventive and therapeutic strategy in patients with migraine. Triptans, considered the mainstay of antimigraine treatment cause vasoconstriction; however,
openaire   +1 more source